Table of contents


Please note that this product was withdrawn from the Community register of designated orphan medicinal products in July 2013 on request of the sponsor.

On 24 July 2009, orphan designation (EU/3/09/658) was granted by the European Commission to Eudax S.R.L., Italy, for tamibarotene for the treatment of acute promyelocytic leukaemia.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Disease / condition
Treatment of acute promyelocytic leukaemia
Date of first decision
EU designation number

Sponsor's contact details

Eudax Srl
Polo Tecnologico
Via Fratelli Cuzio, 42
27100 Pavia
Tel. +39 03 821 750 652
Fax +39 03 821 750 669

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating